ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
23 August 2007 - 9:00PM
PR Newswire (US)
Protocols on ImmuneRegen's Homspera(TM) Submitted to RFI,
'Therapeutic Countermeasures against CDC Category A and B Threat
Agents' SCOTTSDALE, Ariz., Aug. 23 /PRNewswire-FirstCall/ --
Research and development biotechnology company ImmuneRegen
BioSciences, Inc. a wholly owned subsidiary of IR BioSciences
Holdings, Inc. (OTC:IRBO.OB) (BULLETIN BOARD: IRBO.OB) , announced
today that it has recently responded to a Request for Information
(RFI) from the Defense Threat Reduction Agency (DTRA) of the
Department of Defense for Therapeutic Countermeasures against CDC
Category A and B Threat Agents. ImmuneRegen made its submission
August 20, 2007 with information on its potential treatment,
Homspera(TM). ImmuneRegen filed a formal response to the RFI
respective to its compound Homspera(TM), currently in development
as a therapeutic and prophylactic countermeasure against multiple
pathogens including multiple biological, chemical and radiological
threats. For the purposes of this request, the RFI submission
focuses primarily on anthrax countermeasures. "We believe that
Homspera is at the forefront of the development of Category A and B
countermeasures," commented Michael Wilhelm, co-founder and CEO of
ImmuneRegen. "Our studies have shown Homspera to be effective in
protecting experimental animals against the lethal effects of
ionizing radiation, infection with anthrax spores, infection with
influenza virus, and to be an adjuvant in influenza vaccine
studies. We believe Homspera's mode of action includes an
immunostimulatory activity that results in enhanced host defenses
against multiple pathogens." Should this RFI lead to further
studies, ImmuneRegen expects to partner with appropriate
governmental agencies, such as USAMRIID (U.S. Army Medical Research
Institute for Infectious Diseases) or AFIP (Armed Forces Institute
of Pathology). About Homspera(TM) Homspera is a generic name used
by the Company to describe the synthetic peptide Sar9, Met
(O2)11-Substance P. Sar9, Met (O2)11-Substance P is an analog of
the naturally occurring human neuropeptide Substance P, which can
be found throughout the body, including in the airways of humans
and many other species. All of the Company's research and
development efforts are early, pre-clinical stage and Homspera(TM),
as Viprovex(R) and Radilex(TM), has only undergone exploratory
studies to evaluate its biological activity in small animals. About
ImmuneRegen BioSciences, Inc. IR BioSciences Holdings, Inc.,
through its wholly owned subsidiary ImmuneRegen BioSciences, Inc.,
is a development stage biotechnology company focused on the
research and development of Homspera(R) and its derivatives
Radilex(TM) and Viprovex(R), which are designed to be used as
countermeasures for multiple homeland security bioterrorism
threats. Homspera is derived from Substance P, a naturally
occurring peptide immunomodulator and homeostatic compound with the
dual effect of improving pulmonary function and the stimulation of
the human immune system. For more information, please visit the
company's website at http://www.immuneregen.com/. Statements about
the Company's future expectations, including statements about the
potential for the Company's drug candidates, science and
technology, and all other statements in this press release other
than historical facts, are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934, and as that term is defined
in the Private Securities Litigation Reform Act of 1995. The
Company intends that such forward-looking statements be subject to
the safe harbors created thereby. These future events may not occur
as and when expected, if at all, and, together with the Company's
business, are subject to various risks and uncertainties. The
Company's actual results could differ materially from expected
results as a result of a number of factors, including the fact that
preliminary results involved only a small number of test mice, the
subsequent investigations were limited in scope, the uncertainties
inherent in research and development collaborations, pre-clinical
and clinical trials and product development programs, (including,
but not limited to the fact that future results or research and
development efforts may prove less encouraging than current results
or cause side effects not observed in current pre-clinical trials)
the evaluation of potential opportunities, the level of corporate
expenditures and monies available for further studies, capital
market conditions, and others set forth in the Company's periodic
report on Form 10-QSB for the three months ended June 30, 2007 and
on Form 10-KSB for the twelve months ended December 31, 2006 as
filed with the Securities and Exchange Commission. There are no
guarantees that any of the Company's proposed products will prove
to be commercially successful. The Company undertakes no duty to
update forward-looking statements. MEDIA CONTACT: W. Jason Grimley
Spelling Communications 310-477-9500 DATASOURCE: ImmuneRegen
BioSciences, Inc. CONTACT: W. Jason Grimley of Spelling
Communications, +1-310-477-9500, , for ImmuneRegen BioSciences,
Inc. Web site: http://www.immuneregen.com/
Copyright